Tumor growth rate as a prognostic factor for metastatic or recurrent adenoid cystic carcinoma of the head and neck patie
- PDF / 782,488 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 47 Downloads / 175 Views
HEAD AND NECK
Tumor growth rate as a prognostic factor for metastatic or recurrent adenoid cystic carcinoma of the head and neck patients treated with carboplatin plus paclitaxel Naoki Fukuda1 · Yu Fujiwara1 · Xiaofei Wang1 · Akihiro Ohmoto1 · Tetsuya Urasaki1 · Naomi Hayashi1 · Yasuyoshi Sato1 · Kenji Nakano1 · Mayu Yunokawa1 · Makiko Ono1 · Junichi Tomomatsu1 · Shunji Takahashi1 Received: 18 April 2020 / Accepted: 5 November 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Purpose Large prospective studies of chemotherapy for metastatic or recurrent adenoid cystic carcinoma (ACC) of the head and neck are lacking due to the rarity of ACC. The aim of this study is to evaluate the efficacy of carboplatin plus paclitaxel toward ACC and perform an exploratory investigation of the prognostic factors to investigate the optimal strategy for metastatic or recurrent ACC. Methods We retrospectively analyzed recurrent or metastatic ACC patients treated with carboplatin plus paclitaxel between April 2007 and September 2019 in our hospital. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were evaluated, and an exploratory analysis of the prognostic factors was conducted. Results A total of 26 ACC patients were enrolled. ORR and DCR were 11.5 and 76.9%; the median PFS and OS were 8.1 and 22.3 months, respectively. From the results of the multivariate analysis, higher (≥ 6%/month) tumor growth rate (TGR) was associated with worse PFS (hazard ratio [HR] 7.00, 95% CI 1.34–36.53, p = 0.02) and OS (HR 29.33, 95% CI 3.38–254.80, p
Data Loading...
